Views
8 years ago

Volumen VI - Trastornos de ansiedad - 11/2012

  • Text
  • Trastornos
  • Ansiedad
  • Zieher
  • Mecanismos
  • Aspectos
  • Miedo
  • Volumen
  • Oxytocin
  • Zorrilla
  • Tratado
Tratado de Psicofarmacología y Neurociencia Volumen VI. Trastornos de ansiedad: aspectos neurobiológicos, mecanismos epigenéticos y abordajes terapéuticos.

A Sánchez Toranzo, F

A Sánchez Toranzo, F Hansen // Distimia y ansiedad7. Casabianca R, Hirsh H. Como equivocarse menos en terapia, un registro para el modelo m.r.i.Segunda edición. Centro de publicaciones Universidad Nacional del Litoral. Gabas Editorial yAsociados. Argentina. 19928. Crisafulli C, Fabbri C, Porcelli S, Drago A, Spina E, De Ronchi D, Serretti A. Pharmacogeneticsof antidepressants. Front Pharmacol 2011;2:6.9. De Lima MS, Hotopf M. Benefits and risks of pharmacotherapy for dysthymia: a systematicappraisal of the evidence. Drug Staf 2003;26(1):55-64.10. De Lima MS, Moncrieff J. A comparison of drugs versus placebo for the treatment of dysthymia.Cochrane Database Syst Rev. 2000;(2):CD00113011. Dixit AR, Crum RM. Prospective stuy of depresión and the risk of heavy alcohol use in women.Am J Psychiatry 2000;157:751-758.12. Diz-Chaves Y. Ghrelin, appetite regulation, and food reward: interaction with chronic stress. IntJ Pept 2011;2011:898450. Epub 2011 Sep 21.13. Feijo Mello A, Juruela MF, Carmine MP, Tyrka AR, Lawrence HP, Carpenter LL, Del Porto JA.Depresión and stress: is there an endophenotype? Rev Bras Psiquiatr 2007; 29(1):13-18.14. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG,Morgan L, Lohr KN. Comparative benefits and harms of secondgeneration antidepressants: backgroundpaper for the American College of Physicians. Ann Intern Med 2008;149:734-50.15. Gorwood P, Lanfumey L, Hamon M. Alcohol dependence and polymorphisms of serotonin-relatedgenes. Med Sci (Paris) 2004;20(12):1132-1138.16. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategicintentions. Am J Psychiatry 2003;160:636-645.17. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression.Neuropsychopharmacol 2004;29(10):176518. Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther2009;124:57-73.19. Houston JP, Kohler J, Ostbye KM, Heinloth A, Perlis RH. Association of catechol-O-methyltransferasevariants with duloxetine response in major depressive disorder. Psychiatry Res2011;189:475-7.20. Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI Antidepressants for major depressivedisorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysisof placebo-controlled randomized trials. J Clin Psychiaryr. 2011 Aug/;72(8):1144-51. Epub 2011Apr 19.21. Jefferson JW. Bupropion extended-release for depressive disorders. Expert Rev Neurother2008;8(5):715-722.22. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology--with emphasis oncytochrome p450. Toxicol Sci 2011;120:1-13.23. Katz G. Tachyphylaxis/tolerance to antidepressants in treatment of dysthymia: results of aretrospective naturalistic chart review study. Psychiatry Clin Neurosci. 2011 Aug/;65(5):499-504.24. Keers R, Bonvicini C, Scassellati C, Uher R, Placentino A, Giovannini C, Rietschel M, HenigsbergN, Kozel D, Mors O, Maier W, Hauser J, Souery D, Mendlewicz J, Schmal C, Zobel A, Larsen ER,Szczepankiewicz A, Kovacic Z, Elkin A, Craig I, McGuffin P, Farmer AE, Aitchison KJ, Gennarelli M.Variation in GNB3 predicts response and adverse reactions to antidepressants. J PsychopharmacolEDITORIAL SCIENS73

LM Zieher - M Zorrilla Zubilete // Tratado de Psicofarmacología y Neurociencia, Volumen VI. Trastornos de Ansiedad: aspectos neurobiológicos, mecanismos epigenéticos y abordajes terapéuticos2011;25:867-74.25. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings inmajor depressive disorder. Mol Psychiatry 2010;15:473-500.26. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, Goldberg R, KucherlapatiR, Papolos DF. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism withthe psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 1996;67:468-72.27. Lalive AL, Rudolph U, Lüscher C, Tan KR. Is there a way to curb benzodiazepine addiction?Swiss Med Wkly .2011 Oct 19/;141:w13277.doi:10.4414/smw.2011.1327728. Larson SL, Owens PL, Ford D, Eaton W. Depressive disorder, dysthymia, and risk of stroke.Thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke2001;32:197929. Lavretsky H, Siddarth P, Kumar A, Reynolds CF, 3rd. The effects of the dopamine and serotonintransporter polymorphisms on clinical features and treatment response in geriatric depression:a pilot study. Int J Geriatr Psychiatry 2008;23:55-9.30. Lee IS, Kim D. Polymorphic metabolism by functional alterations of human cytochrome P450enzymes. Arc Pharm Res 2011;34:1799-816.31. Le-Niculescu H, McFarland MJ, Odgen CA, Balaraman Y, Patel S, Tan J, Rodd ZA, Paulus M,Geyer MA, Edenberg HJ, Glatt SJ, Faraone SV, Nurnberger JI, Kuzenski R, Tsuang MT, Niculescu AB.Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animalmodel of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet2008;147B(2):134-166.32. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant, AJ, Papanicolaou GJ,Laje G, Fava M, Trivedi MH, Wisniewski S. R., H., M. Variation in the gene encoding the serotonin 2A receptoris associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78:804-814.33. Murphy DL, Lerner A, Ruduick G, Lesch KP. Serotonin transporter: gene, genetic disorders, andpharmacogenetics. Molecular Interventions 2004;4:109-123.34. Narasimhan S, Lohoff FW. Pharmacogenetics of antidepressant drugs: current clinical practiceand future directions. Pharmacogenomics 2012;13:441-64.35. Nelson DR. The cytochrome p450 homepage. Hum Genomics 2009;4:59-65.36. Niculescu AB III, Akiskal HS. Proposed endophenotypes of dysthymia: evolutionary, clinical andpharmacogenomic considerations. Molecular Psychiatry 2001;6:363-366.37. Oude Voshaar RC. Benzodiazepin addiction: a silent addiction among older people. TijdschrGerontol Geriatr 2012 Jun/;43(3):137-147.38. Perroud N, Aitchison KJ, Uher R, Smith R, Huezo-Diaz P, Marusic A, Maier W, Mors O,Placentino A, Henigsberg N, Rietschel M, Hauser J, Souery D, Kapelski P, Bonvicini C, Zobel A,Jorgensen L, Petrovic A, Kalember P, Schulze TG, Gupta B, Gray J, Lewis CM, Farmer AE, McGuffinP, Craig I. Genetic predictors of increase in suicidal ideation during antidepressant treatment in theGENDEP project. Neuropsychopharmacology 2009;34:2517-28.39. Porcelli S, Fabbri C, Drago A, Gibiino S, De Ronchi D, Serretti A. Genetics and antidepressants:Where we are. Clin Neuropsychiatry 2011a;8:99-150.40. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism(5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol2012;22:239-58.74

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015